Medical Costs for Managing Chronic Kidney Disease and Related Complications in Patients With Chronic Kidney Disease and Type 2 Diabetes

, , , , , ,
Supplements and Featured Publications, Patients With Diabetes and Chronic Kidney Disease: ACE Inhibitor or ARB Treatment, Medical Costs for Disease Management, and the FINE-CKD Model to Evaluate Economic Value of Finerenone, Volume 27, Issue 20


Objective: To provide cost estimates for chronic kidney disease (CKD) management and major CKD complications among patients with CKD and type 2 diabetes (T2D). Study Design: A retrospective cohort study of 52,599 adults with CKD and T2D using Optum Clinformatics claims data from 2014 to 2019.

Methods: Medical costs associated with CKD management, renal replacement therapies (RRTs), major CKD complications (eg, myocardial infarction, stroke, heart failure, atrial fibrillation, and hyperkalemia), and death were estimated using generalized estimating equations adjusting for baseline demographics, complications, and medical costs. Costs for CKD management, RRT, and major CKD complications were assessed in 4-month cycles. Mortality costs were assessed in the month before death.

Results: The estimated 4-month CKD management costs ranged from $7725 for stage I to II disease to $11,879 for stage V (without RRT), with high additional costs for dialysis and kidney transplantation ($87,538 and $124,271, respectively). The acute event costs were $31,063 for heart failure, $21,087 for stroke, and $21,016 for myocardial infarction in the first 4 months after the incident event, which all decreased substantially in subsequent 4-month cycles. The acute event costs of atrial fibrillation and hyperkalemia were $30,500 and $31,212 with hospitalization, and $5162 and $1782 without. The costs associated with cardiovascular-related death, renal-related death, and death from other causes were $17,031, $12,605, and $9900, respectively.

Conclusions: Management of CKD and its complications incurs high medical costs for patients with CKD and T2D. Results from this study can be used to quantify the economic profile of emerging treatments and inform decision-making.

Am J Manag Care. 2021;27:S369-S374.
For author information and disclosures, see end of text.


Chronic kidney disease (CKD) is prevalent, and it is estimated that it will affect about 15% of adults or 37 million people in the United States in 2021.1 Diabetes is one of the leading causes of CKD and kidney failure. About 1 in 3 US adults with diabetes has CKD, and CKD with diabetes accounts for approximately 39% of end-stage renal disease (ESRD) cases in the United States.1 Moreover, CKD is associated with an increased risk of cardiovascular (CV) diseases and all-cause mortality.2 The risk of heart failure, atrial fibrillation, stroke, and coronary heart disease is approximately double in patients with CKD.3-7 The adjusted mortality is also twice as high among Medicare beneficiaries with CKD compared with those without CKD.8

CKD poses a substantial economic burden. Medicare spending for all beneficiaries who had CKD exceeded $120 billion in 2017, representing 33.8% of total Medicare fee-for-service spending.9 On an individual level, annual Medicare spending was $16,112 per patient for those with CKD and increased to $19,739 per patient for those with CKD and diabetes.9 In addition to general CKD management, addressing CV complications can be costly. Approximately 29% of the total inpatient hospitalization spending for those with CKD resulted from admissions to treat CV complications.9 Heart failure was associated with an incremental per-person per-year Medicare cost of $19,944 among patients with CKD.8 Hyperkalemia is another complication that is common among patients with CKD, and it is associated with substantial health care costs.10,11 Specifically, hyperkalemia was associated with an increased 1-year cost of $21,857 in patients with CKD and $20,657 in patients with diabetes.10

Current treatment strategies for patients with CKD and type 2 diabetes (T2D) focus on CV risk reduction, blood pressure control, glycemic control, and lipid-lowering therapy.12 For example, the current Kidney Disease: Improving Global Outcomes (KDIGO) guidelines recommend the use of renin-angiotensin-aldosterone system-blocking agents including angiotensin-converting enzyme inhibitors (ACEis) or angiotensin II receptor blockers (ARBs) in patients with CKD and diabetes who have hypertensive symptoms.13 Available evidence strongly indicates that the use of ACEis or ARBs yields a significant renal protective effect, reducing albuminuria and the risk of ESRD in this patient group.12 Several emerging treatments, such as finerenone and sodium-glucose cotransporter-2 inhibitors (SGLT2is), have demonstrated clinical benefits in terms of preventing CV diseases in patients with CKD and T2D, slowing down the progression of kidney disease, and reducing the risk of death.14-18

To evaluate whether these clinical benefits translate to real-world economic benefit (ie, cost-effectiveness), it is essential to quantify the key cost components associated with the management of CKD and related complications in patients with CKD and T2D. However, knowledge gaps exist regarding the health care costs associated with general CKD management at different disease stages and major complications (including myocardial infarction [MI], heart failure, stroke, atrial fibrillation, and hyperkalemia) in patients with CKD and T2D. This study aims to provide the most up-to-date estimates of cost components related to general CKD management and major CKD complications using a regression-based approach. Results will facilitate the parameterization of economic models and quantify the economic burden in this population using the most recent data.


Study Design and Population

This retrospective cohort study identified adult patients with T2D and CKD using Optum Clinformatics claims data from 2014 to 2019. The Optum claims database is a single-payer source of administrative health claims with approximately 15 to 20 million annual covered enrollees across all states in the United States. Enrollees may be covered by commercial health plans or Medicare Advantage. The administrative claims were submitted for payment by providers and pharmacies and were verified, adjudicated, and de-identified.

T2D was identified using a modified version of the Electronic Medical Records and Genomics algorithm, developed to identify patients with T2D in electronic medical records with high specificity.19 Patients without observed insulin use were required to have at least 1 medical claim with a T2D diagnosis and at least 1 prescription claim for antidiabetic medication. Patients with observed insulin use were required to have (1) at least 1 medical claim with a T2D diagnosis and at least 1 prescription claim for antidiabetic therapy prior to the first insulin prescription; or (2) at least 2 T2D diagnoses on different dates among those without antidiabetic prescription claims. Patients with records of other types of diabetes (including type 1 diabetes, diabetes due to underlying conditions, drug- or chemical-induced diabetes, and other specified diabetes) were excluded.

CKD was identified using at least 1 inpatient or at least 2 outpatient CKD claims on distinct dates. Evidence of CKD included having diagnosis codes for CKD or ESRD, or procedure codes for renal replacement therapies (RRT), including dialysis and kidney transplantation. Only patients with known CKD stage based on diagnosis codes were included.

The study index date was defined as the first date when both T2D and CKD definitions were met. Patients were required to have continuous enrollment for 1 year before (baseline period) and at least 4 months after the index date. Patients covered by health maintenance organizations during the baseline or study period were excluded from the study sample because their recorded health care expenditures may not accurately reflect their medical care usage.

Study Outcomes

This study assessed medical costs from the payer’s perspective, from the patient’s index date to disenrollment, death, or end of data availability. Cost components included CKD management, RRT, major CKD complications, and death. The costs for CKD management, RRT, and major CKD complications were reported in 4-month cycles, which was a commonly evaluated cycle length in clinical trials in this population.15,17 Mortality costs were assessed in the month prior to death.

The costs of general CKD management were estimated by CKD stage, classified as stage I to II, stage III, stage IV, and stage V without RRT.20 The costs of RRT were assessed separately, including dialysis costs and kidney transplantation costs. Major CKD complications included MI, heart failure (with hospitalization), stroke, hyperkalemia (with and without hospitalization), and atrial fibrillation (with and without hospitalization). Death was classified as CV-related, renal-related, or from other causes based on the primary diagnosis or procedure codes during hospitalization in the month of death because direct information on the cause of death was not available.

Events of interest were identified using International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) diagnosis codes, and Current Procedural Terminology, Healthcare Common Procedure Coding System, and ICD-9-CM or ICD-10 Procedure Coding System procedure codes. All medical costs were inflated to 2020 US$ using the medical care component of the Consumer Price Index.

Statistical Analysis

Descriptive analyses were performed for patient characteristics during baseline. Mean and standard deviation were reported for continuous variables, and frequency counts and percentages were used for categorical variables. Median and interquartile range were calculated for baseline medical costs.

A generalized estimating equation (GEE) regression with a normal distribution and an exchangeable correlation structure was used to model the monthly costs associated with the management of CKD, RRT, major CKD complications, and death, adjusting for age at index date, sex, baseline complications, and baseline medical costs (detailed model specification information is displayed in Figure 1). A GEE regression model is a technique for obtaining regression estimates in multilevel data. It was used to account for the within-subject correlations in our longitudinal claims data with repeated measurements. CKD management costs (excluding costs associated with RRT, major CKD complications, and death) were estimated on a monthly basis and were summarized in a 4-month period for CKD stages I to II through V without RRT. The costs for major CKD complications (eg, MI, heart failure, stroke), dialysis, and kidney transplantation were estimated for 2 phases. Acute costs included the costs occurring during the month of the event onset and the subsequent 3 months (ie, 4 months in total); postacute costs included costs during subsequent follow-up and were reported in 4-month cycles. Similar to Kähm et al, these later months were assumed to reflect the ongoing impact of the complication, regardless of whether the particular event recurred following the incident month.21 Only acute costs were estimated for hyperkalemia and atrial fibrillation due to their relatively short-term impact on costs.

SAS 9.4 software (SAS Institute, Cary, NC) was used for all statistical analyses.


Sample and Patient Characteristics

The study sample included 52,599 adult patients with T2D and CKD (Figure 2). Table 1 describes patients’ baseline demographics and clinical characteristics. Patients were 71 years of age on average; 49% were female and 60% were White. The majority of patients were covered by Medicare Advantage (80%). Most patients had a CKD diagnosis at index date indicating CKD stage III (68%), followed by stage II (21%). Diagnoses of hypertension (92%) and hyperlipidemia (84%) were very common in the study sample, which also had a relatively high prevalence of recorded microvascular complications (32%), ischemic heart diseases (30%), and anemia (27%). For the major CKD complications of interest, the prevalence was moderate to low during the 1-year baseline period: heart failure (16%), atrial fibrillation (13%), MI (7%), hyperkalemia (6%), and stroke (5%). Baseline all-cause medical costs were $16,995 annually on average.

Cost Estimates

Table 2 shows the cost estimates for CKD management, RRT, major CKD complications, and death. The estimated 4-month CKD management costs for stage I to II were $7725 and increased to $11,879 for stage V (without RRT), with the largest increase (+$1881) from stage III to IV. The estimated acute event costs for dialysis and kidney transplantation were $87,538 and $124,271, respectively. The costs decreased substantially to $49,573 and $7079 in the subsequent 4-month cycles, respectively.

For major CKD complications, the estimates of acute cost in the first 4 months after the incident event were $21,016 for MI, $21,087 for stroke, and $31,063 for heart failure. For patients who experienced a hospitalization with atrial fibrillation, their acute costs were nearly 6 times higher than those without a hospitalization ($30,500 vs $5162). Similarly, the acute cost of hyperkalemia was $31,212 with hospitalization and $1782 without. In subsequent 4-month cycles, the cost of major CKD complications decreased to $4931 for heart failure, $2327 for stroke, and $1941 for MI. In the month before death, the costs associated with CV-related death, renal-related death, and death from other causes were $17,031, $12,605, and $9900, respectively.


This study summarizes the real-world economic impact associated with CKD management, RRT, major CKD complications, and death in patients with CKD and T2D, using a large US administrative claims database. The results show that costs associated with CKD management increase with disease severity, and the costs were substantially higher with RRT. CKD complications were associated with high costs during the initial months, with acute costs nearly double or triple the amount associated with regular CKD management without RRT. In addition, both CV-related and renal-related death incurred high costs in this patient population.

Given the rising prevalence of T2D and the high prevalence of CKD among patients with T2D, slowing down CKD progression and preventing these costly complications can substantially reduce the economic burden associated with this population.1,22 For example, by reducing the incidence of heart failure by 1 percentage point among patients with T2D and CKD, a Medicare Advantage plan of 1 million enrollees could save more than $18.6 million in acute costs (using the estimated acute cost for heart failure [$31,063]).23,24 Similarly, if a treatment can yield a percentage point reduction in the incidence of patients progressing to dialysis, the health care plan can save approximately $52 million in dialysis initiation costs and $30 million in each subsequent 4-month cycle.

This study found acute costs of major complications commonly seen in CKD and T2D to be much higher than postacute costs, which is largely consistent with results reported in published studies. For example, a retrospective analysis of 2002 to 2009 Medicare claims data among older MI survivors reported a mean health care cost of $21,416 during the calendar quarter of the MI and $3574 for each calendar quarter post MI.25 A systematic literature review of journal articles published between 2014 and 2020 on heart failure–related costs reported a mean cost of $11,315 during the first month after a heart failure event, and a mean monthly cost during the entire first year post heart failure of $2427.26 Another retrospective analysis assessed the cost of hyperkalemia using the MarketScan claims database; the 1-month cost after a hyperkalemia event was $5994 and the average monthly cost within the first year was $2654.10 Our results were largely in line with these previous findings in patients with CKD and T2D after controlling for patients’ baseline demographics and complications.

Patients with CKD and T2D should be treated with a comprehensive strategy to reduce the risk of kidney disease progression and CV disease; the strategy usually includes blood pressure control by ACEis or ARBs, glycemic control by metformin and other antihyperglycemics, antiplatelet therapy with aspirin in those with established CV disease, and various lifestyle interventions.13 Several emerging treatments demonstrated promising efficacy in preventing CV- and renal-related events in recent trials. Canagliflozin, dapagliflozin, and empagliflozin, the first 3 SGLT2is approved by the United States Food and Drug Administration (FDA), were shown to decrease the risk of renal and CV outcomes in patients with CKD and T2D.14-16,18 Finerenone, a first-in-class nonsteroidal, selective mineralocorticoid receptor antagonist recently approved by the FDA in adults with CKD and T2D, was also shown to lower the risk of renal and CV outcomes in this patient population in the FIDELIO-DKD trial (NCT02540993).17,27 To formally evaluate the different roles that these emerging treatments can fill in the management of CKD and T2D, rigorous economic models are needed to systematically assess their cost effectiveness, especially potential cost reductions in the setting of common CKD complications. The current study provides accurate estimates for the key cost components relevant to managing patients with CKD and T2D from a US payer’s perspective, which can be used to facilitate the parameterization of such cost-effectiveness models.


The findings of this study need to be seen in light of several limitations. First, although this study used GEE regression analysis to provide cost estimates, adjusting for patient demographics, baseline complications, and baseline medical costs, the model did not control for other chronic comorbidities, such as hypertension and hyperlipidemia. This is not expected to impact the results significantly, given that age is a strong predictor of comorbidities.21 Nonetheless, there may be remaining confounding due to clinical characteristics (eg, disease duration and smoking status) that cannot be observed in retrospective claims data.21 Second, this study was subject to the typical limitations of retrospective studies based on health care claims data, such as possible errors or omissions of claims. Certain comorbidities may be underestimated due to coding incompleteness, inaccuracies, or misclassification. CV-related or renal-related death was assigned based on the primary diagnosis or procedure codes during the hospitalization in the month of death, given that the cause of death cannot be evaluated directly in claims data. In addition, the cost items in this study reflect the adjudicated reimbursement rate, instead of actual cost. It is possible that some medical items were not claimed and thus not captured in the data. Third, the Optum Clinformatics claims data used in this study were from a single payer source (eg, UnitedHealth Group). Formularies of this specific payer may have impacted health care resource utilization and medical costs incurred. Future studies are needed to evaluate whether results of this study would be transferable to other payers. Fourth, patients in this study were enrolled in commercial plans or Medicare Advantage, and were required to have a known CKD stage based on diagnosis codes. The cost estimates may only apply to patients meeting the study criteria.


CKD incurs high health care costs in adult patients with T2D, which increase with more severe disease stages. RRT and management of major CKD complications, especially during the acute period immediately after the onset of the complications, are the most expensive components. The results demonstrate the imminent need for appropriate monitoring and treatment to avoid downstream costs in this patient population. The cost estimates from this study may also support the parametrization of economic models and help clinicians, payers, and other health care decision-makers determine the cost-effectiveness of interventions for CKD and T2D.

Author affiliations:
Analysis Group, Los Angeles, CA, New York, NY (KB, EF, JS, KY), Bayer Pharmaceuticals, Whippany, NJ (YD, SXK, RS).

Funding source: This supplement was supported by Bayer AG.

Author disclosures: Dr Betts, Ms Faust, Dr Song, and Ms Yang have been employees of Analysis Group, a consulting company that has provided paid consulting services to Bayer Pharmaceuticals, which funded the development and conduct of this study and manuscript. Dr Du, Dr Kong, and Dr Singh have been employees of Bayer Pharmaceuticals, sponsor of the study, have owned stock in Bayer Pharmaceuticals, and have disclosed that a Bayer Pharmaceuticals drug for chronic kidney disease in patients with type 2 diabetes is approved in the United States. Dr Du has also received consulting fees from faculty emeritus at the University of Washington.

Authorship information: Concept and design (KB, YD, EF, SXK, RS, JS); analysis and interpretation of data (KB, YD, EF, SXK, RS, JS, KY); drafting of the manuscript (RS, KY); critical revision of the manuscript for important intellectual content (YD, SXK, RS); statistical analysis (KB, EF, JS, KY); provision of study materials or patients (YD, RS); obtaining funding (RS); administrative, technical, or logistic support (YD); supervision (YD, RS).

Address correspondence to: Rakesh Singh, PhD;


1. Chronic kidney disease in the United States, 2021. Centers for Disease Control and Prevention. Updated March 4, 2021. Accessed September 8, 2021.

2. Drawz P, Rahman M. Chronic kidney disease. Ann Intern Med. 2015;162(11):ITC1-ITC16. doi:10.7326/ AITC201506020

3. Gansevoort RT, Correa-Rotter R, Hemmelgarn BR, et al. Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. Lancet. 2013;382(9889):339-352. doi:10.1016/S0140- 6736(13)60595-4

4. Alonso A, Lopez FL, Matsushita K, et al. Chronic kidney disease is associated with the incidence of atrial fibrillation: the Atherosclerosis Risk in Communities (ARIC) study. Circulation. 2011;123(25):2946- 2953. doi:10.1161/CIRCULATIONAHA.111.020982

5. Abramson JL, Jurkovitz CT, Vaccarino V, Weintraub WS, McClellan W. Chronic kidney disease, anemia, and incident stroke in a middle-aged, community-based population: the ARIC Study. Kidney Int. 2003;64(2):610-615. doi:10.1046/j.1523-1755.2003.00109.x

6. Astor BC, Coresh J, Heiss G, Pettitt D, Sarnak MJ. Kidney function and anemia as risk factors for coronary heart disease and mortality: the Atherosclerosis Risk in Communities (ARIC) Study. Am Heart J. 2006;151(2):492-500. doi:10.1016/j.ahj.2005.03.055

7. Kottgen A, Russell SD, Loehr LR, et al. Reduced kidney function as a risk factor for incident heart failure: the atherosclerosis risk in communities (ARIC) study. J Am Soc Nephrol. 2007;18(4):1307-1315. doi:10.1681/ASN.2006101159

8. Johansen KL, Chertow GM, Foley RN, et al. US Renal Data System 2020 annual data report: epidemiology of kidney disease in the United States. Am J Kidney Dis. 2021;77(4)(suppl 1):A7-A8. doi:10.1053/j. ajkd.2021.01.002

9. Saran R, Robinson B, Abbott KC, et al. US Renal Data System 2019 annual data report: epidemiology of kidney disease in the United States. Am J Kidney Dis. 2020;75(1)(suppl 1):A6-A7. doi:10.1053/j. ajkd.2019.09.003

10. Betts KA, Woolley JM, Mu F, Xiang C, Tang W, Wu EQ. The cost of hyperkalemia in the United States. Kidney Int Rep. 2017;3(2):385-393. doi:10.1016/j.ekir.2017.11.003

11. Betts KA, Woolley JM, Mu F, McDonald E, Tang W, Wu EQ. The prevalence of hyperkalemia in the United States. Curr Med Res Opin. 2018;34(6):971-978. doi:10.1080/03007995.2018.1433141

12. Umanath K, Lewis JB. Update on diabetic nephropathy: core curriculum 2018. Am J Kidney Dis. 2018;71(6):884-895. doi:10.1053/j.ajkd.2017.10.026

13. Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2020 clinical practice guideline for diabetes management in chronic kidney disease. Kidney Int. 2020;98(4S):S1-S115. doi:10.1016/j.kint.2020.06.019

14. Perkovic V, Jardine MJ, Neal B, et al; CREDENCE Trial Investigators. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Eng J Med. 2019;380(24):2295-2306. doi:10.1056/NEJMoa1811744

15. Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al; DAPA-CKD Trial Committees and Investigators. Dapagliflozin in patients with chronic kidney disease. New Engl J Med. 2020;383(15):1436-1446. doi:10.1056/NEJMoa2024816

16. Wheeler DC, Stefánsson BV, Jongs N, et al; DAPA-CKD Trial Committees and Investigators. Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial. Lancet Diabetes Endocrinol. 2021;9(1):22-31. doi:10.1016/S2213-8587(20)30369-7

17. Bakris GL, Agarwal R, Anker SD, et al; FIDELIO-DKD Investigators. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med. 2020;383(23):2219-2229. doi:10.1056/ NEJMoa2025845

18. Levin A, Perkovic V, Wheeler DC, et al; EMPA-REG OUTCOME Investigators. Empagliflozin and cardiovascular and kidney outcomes across KDIGO risk categories: post hoc analysis of a randomized, doubleblind, placebo-controlled, multinational trial. Clin J Am Soc Nephrol. 2020;15(10):1433-1444. doi:10.2215/ CJN.14901219

19. Kho AN, Hayes MG, Rasmussen-Torvik L, et al. Use of diverse electronic medical record systems to identify genetic risk for type 2 diabetes within a genome-wide association study. J Am Med Inform Assoc. 2012;19(2):212-218. doi:10.1136/amiajnl-2011-000439

20. Levey AS, Stevens LA, Coresh J. Conceptual model of CKD: applications and implications. Am J Kidney Dis. 2009;53(3)(suppl 3):S4-S16. doi:10.1053/j.ajkd.2008.07.048

21. Kähm K, Laxy M, Schneider U, Rogowski WH, Lhachimi SK, Holle R. Health care costs associated with incident complications in patients with type 2 diabetes in Germany. Diabetes Care. 2018;41(5):971-978. doi:10.2337/dc17-1763

22. National diabetes statistics report, 2020. Centers for Disease Control and Prevention. Updated August 28, 2020. Accessed September 8, 2021.

23. United States Renal Data System. 2020 USRDS annual data report: epidemiology of kidney disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. 2020. Accessed October 7, 2021.

24. Hasche J, Ward C, Schluterman, N. Diabetes occurrence, costs, and access to care among Medicare beneficiaries aged 65 years and over. Centers for Medicare and Medicaid Services Office of Enterprise Data & Analytics. 2017. Accessed October 7, 2021.

25. Yang E, Stokes M, Johansson S, et al. Clinical and economic outcomes among elderly myocardial infarction survivors in the United States. Cardiovasc Ther. 2016;34(6):450-459. doi:10.1111/1755-5922.12222

26. Urbich M, Globe G, Pantiri K, et al. A systematic review of medical costs associated with heart failure in the USA (2014-2020). Pharmacoeconomics. 2020;38(11):1219-1236. doi:10.1007/s40273-020-00952-0

27. FDA approves drug to reduce risk of serious kidney and heart complications in adults with chronic kidney disease associated with type 2 diabetes. US Food & Drug Administration. July 9, 2021. Accessed September 8, 2021.